1.Meldrum, BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000;130(4S Suppl):1007S–1015S.
2.Oliet, SH, Mothet, JP. Regulation of N-methyl-d-aspartate receptors by astrocytic d-serine. Neuroscience 2009;158:275–283.
3.Chen, HS, Lipton, SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006;97:1611–1626.
4.Goff, DC, Coyle, JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367–1377.
5.Essa, MM, Braidy, N, Vijayan, KRet al. Excitotoxicity in the pathogenesis of autism. Neurotox Res 2013;23:393–400.
6.Gandal, MJ, Anderson, RL, Billingslea, ENet al. Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia? Genes Brain Behav 2012;11:740–750.
7.Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742–755.
8.Walther, S, Koschorke, P, Horn, Het al. Objectively measured motor activity in schizophrenia challenges the validity of expert ratings. Psychiatry Res 2009;169:187–190.
9.Andreasen, NC. The evolving concept of schizophrenia: from Kraepelin to the present and future. Schizophr Res 1997;28:105–109.
10.Berle, JO, Hauge, ER, Oedegaard, KJet al. Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression. BMC Res Notes 2010;3:149.
11.Homayoun, H, Stefani, MR, Adams, BWet al. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004;29:1259–1269.
12.Heresco-Levy, U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs 2005;10:827–844.
13.Surges, R, Volynski, KE, Walker, MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord 2008;1:13–24.
14.Tariot, PN, Farlow, MR, Grossberg, GTet al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317–324.
15.Zoccolella, S, Santamato, A, Lamberti, P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat 2009;5:577–595.
16.Yahn, SL, Watterson, LR, Olive, MF. Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse 2013;6:1–12.
17.Deutsch, SI, Pepe, GJ, Burket, JA et al. D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Brain Res 2012;1439:96–107.
18.Dean, O, Giorlando, F, Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011;36:78–86.